Chris Howe

Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.

David J. Handelsman, Ann J. Conway, Chris Howe et al. · The Journal of Clinical Endocrinology & Metabolism · 1996 · 151 citations · Full text

Spermatogenesis, Testosterone Depot, Hormonal Contraceptive +21

An analysis of testosterone implants for androgen replacement therapy

David J. Handelsman, Maryanne Mackey, Chris Howe et al. · Clinical Endocrinology · 1997 · 97 citations

Erectile Dysfunction, Gynecology, Surgery +16

Suppression of cortisol responses to exogenous adrenocorticotrophic hormone, and the occurrence of side effects attributable to glucocorticoid excess, in cats during therapy with megestrol acetate and prednisolone.

Deborah Middleton, A. D. J. Watson, Chris Howe et al. · PubMed · 1987 · 62 citations · Full text

Glycogen Deposition, Veterinary Research, Education +18

Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial

Patricia A. Mote, Anne Gompel, Chris Howe et al. · Breast Cancer Research and Treatment · 2015 · 43 citations

Infertility, Hormonal Contraceptive, Fertility +13

Adrenal and gonadal contributions to urinary excretion and plasma concentration of epitestosterone in men — effect of adrenal stimulation and implications for detection of testosterone abuse

Andrew T. Kicman, Sarah B. Coutts, David J. Handelsman et al. · Clinical Endocrinology · 1999 · 21 citations